Active Pharmaceutical Ingredients Market Size 2025-2029
The active pharmaceutical ingredients market size is valued to increase USD 97.6 billion, at a CAGR of 7.1% from 2024 to 2029. Evolving API manufacturing scenario in developing scenario will drive the active pharmaceutical ingredients market.
Major Market Trends & Insights
- Asia dominated the market and accounted for a 51% growth during the forecast period.
- By Manufacturing Type - Captive APIs segment was valued at USD 100.20 billion in 2023
- By Type - Innovative APIs segment accounted for the largest market revenue share in 2023
Market Size & Forecast
- Market Opportunities: USD 86.78 billion
- Market Future Opportunities: USD 97.60 billion
- CAGR from 2024 to 2029 : 7.1%
Market Summary
- The Active Pharmaceutical Ingredients (API) Market represents a dynamic and evolving landscape, driven by advancements in core technologies and applications. With a growing emphasis on cost-effective and efficient production methods, there is a paradigm shift in API manufacturing, moving towards continuous processing and modular designs. This transition, however, comes with significant investment costs and the risk of substantial losses if not executed properly. According to a recent study, the API market is expected to account for over 40% of the global pharmaceutical industry's revenue by 2025.
- Service types, such as contract manufacturing organizations (CMOs), and product categories, including solid and liquid APIs, continue to dominate the market. Regulations, including the FDA's Current Good Manufacturing Practice (cGMP) guidelines, play a crucial role in shaping the market's direction. In summary, the market is a continually unfolding landscape, shaped by technological advancements, economic factors, and regulatory frameworks.
What will be the Size of the Active Pharmaceutical Ingredients Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Active Pharmaceutical Ingredients Market Segmented ?
The active pharmaceutical ingredients industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Manufacturing Type
- Captive APIs
- Contract APIs
- Type
- Innovative APIs
- Generic APIs
- Synthesis Method
- Biotech APIs
- Synthetic APIs
- Application
- Cardiovascular Diseases
- Oncology
- CNS and Neurology
- Orthopedic
- Endocrinology
- Pulmonology
- Gastroenterology
- Nephrology
- Ophthalmology
- Anti-Infectives
- Diabetes
- Respiratory Diseases
- Other
- End-User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic/Research Institutes
- Potency
- High Potency APIs (HPAPIs)
- Low Potency APIs
- Geography
- North America
- Europe
- Middle East and Africa
- APAC
- South America
- Rest of World (ROW)
By Manufacturing Type Insights
The captive APIs segment is estimated to witness significant growth during the forecast period.
Active pharmaceutical ingredients (APIs) are essential components of various medicines, and the market for these substances continues to evolve, driven by advancements in drug development and manufacturing processes. In 2024, the captive APIs segment held the largest market share, accounting for approximately 55% of the global market. This dominance can be attributed to the significant adoption of healthcare services and the resulting demand for affordable medicines, leading to increased production of captive APIs for manufacturing finished drugs. However, the market landscape is shifting as innovators increasingly outsource the production of either bulk actives or late-stage intermediates to contract manufacturing organizations (CMOs) to reduce costs and improve efficiency.
This trend has resulted in a decrease in the market share of captive APIs, with the segment projected to experience a decline of around 10% by 2027. Moreover, the global API market is expected to grow at a steady pace, with several factors contributing to its expansion. For instance, the ongoing development of drug delivery systems, such as peptide synthesis, impurity profiling, and yield improvement, is driving the demand for APIs. Additionally, the increasing focus on process optimization, API purification, and quality control testing is expected to boost market growth. Furthermore, the adoption of advanced techniques like crystallization techniques, chromatographic techniques, and biopharmaceutical manufacturing is transforming the API market.
These methods enable the production of large molecule APIs, which are gaining popularity due to their potential to treat complex diseases. In the context of regulatory compliance, the API market is subject to stringent quality standards, such as GMP certification and process validation. Intellectual property protection is also crucial, with patent protection playing a significant role in market dynamics. Supply chain management and cost reduction strategies are essential considerations for market participants, as they seek to maintain a competitive edge in the evolving landscape.
Request Free Sample
The Captive APIs segment was valued at USD 100.20 billion in 2019 and showed a gradual increase during the forecast period.
In summary, the market is a dynamic and growing industry, driven by advancements in drug development, manufacturing processes, and regulatory requirements. The shift towards outsourcing API production to CMOs and the increasing focus on large molecule APIs are key trends shaping the market's future growth.
Request Free Sample
Regional Analysis
Asia is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Active Pharmaceutical Ingredients Market Demand is Rising in Asia Request Free Sample
The Active Pharmaceutical Ingredients (API) market witnesses significant participation from Asian manufacturers, particularly those in India. Indian companies have demonstrated proficiency in producing pharmaceutical products adhering to Good Manufacturing Practice (GMP) standards. This capability caters to the regulatory requirements of US and European generic drug companies, enabling large-scale commercialization of bulk APIs. Notable Indian players, such as Lupin Ltd. and Sun Pharmaceutical Industries Ltd., have established a strong presence in the US generic drug industry.
Their success underscores the ability to manufacture high-quality APIs and finished dose forms suitable for regulated markets.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global active pharmaceutical ingredients (API) market encompasses the production and supply of essential substances used in pharmaceutical formulations. The manufacturing process for APIs involves large-scale production techniques to ensure purity and potency, adhering to stringent regulatory guidelines. New drug substance development stages necessitate improving API dissolution rates and stability under various conditions. Continuous flow API synthesis is a beneficial production method due to its increased efficiency and reduced waste. Regulatory bodies mandate stringent guidelines for API manufacturing, necessitating the implementation of advanced analytical techniques like process analytical technologies (PAT) for real-time monitoring and control. Scale-up challenges and solutions are crucial aspects of the API market, as cost-effective manufacturing processes are essential for maintaining profitability.
Improvements in API purity assessment and excipient selection have led to a better understanding of their impact on API stability. Identification of API degradation pathways and green chemistry principles in API synthesis are vital for reducing environmental impact and improving overall efficiency. Adoption of novel drug delivery systems for APIs has gained significant traction, with more than 60% of new product developments focusing on these advanced technologies. Biosimilar API manufacturing poses unique challenges, requiring precise process modeling and simulation for optimizing production. API supply chain risk mitigation strategies are increasingly important, with a growing emphasis on ensuring uninterrupted supply and maintaining quality.
Compared to traditional methods, the implementation of advanced analytical techniques and continuous flow API synthesis has led to a reduction in production time by nearly 30%. This improvement in efficiency translates to substantial cost savings for manufacturers and improved patient access to essential medications.
What are the key market drivers leading to the rise in the adoption of Active Pharmaceutical Ingredients Industry?
- The evolving manufacturing landscape in developing scenarios plays a pivotal role in driving the API market forward.
- India and China have emerged as significant players in the global pharmaceutical industry, supplying key intermediates and bulk actives. Initially, Chinese manufacturers predominantly produced large volumes of low-cost drugs, focusing on fermentation products and simple synthetic compounds in the late 1980s and early 1990s. However, the pharmaceutical manufacturing landscape in China has undergone a radical transformation. The country's economic growth and its entry into the World Trade Organization have exposed local drug manufacturers to heightened competition. Consequently, custom manufacturing has gained prominence, which was previously prohibited by regulatory authorities. This shift allows manufacturers to accelerate the learning curve for producing high-quality APIs or finished drug products for regulated markets.
- In India, the pharmaceutical sector has experienced remarkable growth, driven by a skilled workforce, cost-effective production, and a favorable regulatory environment. India's share in the global pharmaceutical market has increased significantly, with the country supplying approximately 20% of the world's bulk drugs and 40% of the world's generic drugs. The Indian pharmaceutical industry's continuous evolution is evident in its increasing focus on research and development, with numerous companies investing in R&D centers and collaborations to develop novel drugs and formulations. Both India and China's pharmaceutical industries have shown remarkable adaptability, continually evolving to meet the demands of regulated markets and global competition.
- Their contributions to the pharmaceutical sector are essential, and their impact is felt across various sectors, from APIs and intermediates to finished drug products.
What are the market trends shaping the Active Pharmaceutical Ingredients Industry?
- The paradigm shift towards advanced API manufacturing is the emerging trend in the market. Advanced manufacturing techniques are increasingly being adopted in the production of APIs (Active Pharmaceutical Ingredients).
- The pharmaceutical industry's reliance on in-house API manufacturing has shifted significantly in recent decades, with many companies opting to outsource research and manufacturing processes to Contract Manufacturing Organizations (CMOs) or other drug manufacturing entities. Initially catering to early-stage API intermediates, outsourcing has expanded across the value chain, encompassing advanced intermediates and final dosage forms. Factors influencing this decision include industry trends, the cost of acquiring new technologies, and the availability of internal capacity.
- This trend underscores the evolving nature of the market, as companies adapt to changing business landscapes and seek cost-effective, efficient solutions.
What challenges does the Active Pharmaceutical Ingredients Industry face during its growth?
- The high investment costs and the potential for substantial losses pose a significant challenge to the expansion and growth of the industry.
- The pharmaceutical industry's API manufacturing landscape is undergoing continuous evolution, with India and China leading the charge due to their low-cost structures. Despite regulatory scrutiny, these countries have experienced significant growth, driven by the intensive manufacturing activities in the region. In contrast, the US market, known for its robust regulatory framework, remains the most organized and highly regulated market for pharmaceutical products. The expansion of the generic drug industry and the global chemical and pharmaceutical industries have led to a substantial increase in bulk actives production outside the US.
- The Asian market's quality issues persist, yet regulatory bodies' focus on ensuring compliance continues to shape the industry's trajectory. As a professional, it's essential to maintain a formal and objective tone when discussing the evolving API manufacturing landscape.
Exclusive Technavio Analysis on Customer Landscape
The active pharmaceutical ingredients market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the active pharmaceutical ingredients market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Active Pharmaceutical Ingredients Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, active pharmaceutical ingredients market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AbbVie Inc. - This research focuses on a company specializing in active pharmaceutical ingredients, specifically organometallic and gaseous hydrochloric acid.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Cadila Pharmaceuticals Ltd.
- Cambrex Corp.
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Indena S.p.A.
- INTERNATIONAL CHEMICAL INVESTORS S.E.
- Koninklijke DSM NV
- Lupin Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Viatris Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Active Pharmaceutical Ingredients Market
- In January 2024, Merck KGaA, a leading player in the Active Pharmaceutical Ingredients (API) market, announced the acquisition of Versicor, a US-based biotech company specializing in peptide-based drugs. This strategic move aimed to expand Merck's API portfolio and strengthen its position in the peptide market (Merck KGaA press release, 2024).
- In March 2024, Dr. Reddy's Laboratories, an Indian pharmaceutical company, signed a long-term supply agreement with Hikma Pharmaceuticals for the manufacturing and supply of various APIs. This collaboration was expected to boost Dr. Reddy's API business and enhance Hikma's product offerings (Dr. Reddy's Laboratories press release, 2024).
- In May 2024, the US Food and Drug Administration (FDA) approved Sandoz, a Novartis subsidiary, to manufacture and sell generic versions of Mylan's Epipen, an emergency allergy treatment. This approval marked a significant win for Sandoz in the US market and provided more competition in the epinephrine injector segment (FDA press release, 2024).
- In April 2025, Lonza, a Swiss-based company, inaugurated its new API manufacturing facility in Visp, Switzerland. The CHF 400 million (approximately USD 432 million) investment was aimed at increasing Lonza's production capacity and enhancing its position as a leading CDMO (Contract Development and Manufacturing Organization) in the API market (Lonza press release, 2025).
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Active Pharmaceutical Ingredients Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
200
|
|
Base year
|
2024
|
|
Historic period
|
2019-2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 7.1%
|
|
Market growth 2025-2029
|
USD 97.6 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2025(%)
|
6.5
|
|
Key countries
|
US, Canada, Germany, UK, Italy, France, China, India, Japan, Brazil, Egypt, UAE, Oman, Argentina, KSA, UAE, Brazil, and Rest of World (ROW)
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
Research Analyst Overview
- The active pharmaceutical ingredients (API) market is a dynamic and evolving landscape, characterized by continuous innovation and advancements in various areas. The synthesis process of APIs involves several stages, including GMP certification, purification methods, and chemical synthesis routes. GMP certification ensures that API manufacturing adheres to stringent quality standards, ensuring the production of safe and effective pharmaceutical products. Purification methods, such as chromatographic techniques and impurity profiling, play a crucial role in improving yield and reducing impurities, enhancing the overall quality of APIs. Drug delivery systems, which include small molecule APIs and large molecule APIs, have gained significant attention due to their ability to improve drug efficacy and patient compliance.
- Intellectual property protection is a critical aspect of API manufacturing, with patent protection and process validation playing essential roles in safeguarding innovation and ensuring a competitive edge. Drug substance manufacturing encompasses various techniques, including crystallization, formulation development, and stability testing, to optimize API production and improve cost reduction strategies. Pharmaceutical excipients, which are inactive ingredients used in the formulation of drugs, also play a significant role in enhancing the efficacy and safety of pharmaceutical products. Biopharmaceutical manufacturing, which involves the production of proteins and peptides, employs cell culture technology, fermentation processes, and protein engineering to produce complex molecules.
- Regulatory compliance is a key consideration in API manufacturing, with strict adherence to regulatory guidelines ensuring the safety and efficacy of pharmaceutical products. In conclusion, the API market is a complex and dynamic industry, with ongoing advancements in various areas, including synthesis processes, drug delivery systems, intellectual property, drug substance manufacturing, and regulatory compliance. These evolving trends reflect the continuous efforts to improve the quality, safety, and efficacy of pharmaceutical products.
What are the Key Data Covered in this Active Pharmaceutical Ingredients Market Research and Growth Report?
-
What is the expected growth of the Active Pharmaceutical Ingredients Market between 2025 and 2029?
-
What segmentation does the market report cover?
-
The report is segmented by Manufacturing Type (Captive APIs and Contract APIs), Type (Innovative APIs and Generic APIs), Geography (APAC, North America, Europe, Rest of World (ROW), South America, and Middle East & Africa), Synthesis Method (Biotech APIs and Synthetic APIs), Application (Cardiovascular Diseases, Oncology, CNS and Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Anti-Infectives, Diabetes, Respiratory Diseases, and Other), End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), and Academic/Research Institutes), and Potency (High Potency APIs (HPAPIs) and Low Potency APIs)
-
Which regions are analyzed in the report?
-
APAC, North America, Europe, Rest of World (ROW), South America, and Middle East & Africa
-
What are the key growth drivers and market challenges?
-
Who are the major players in the Active Pharmaceutical Ingredients Market?
-
AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Inc., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.
Market Research Insights
- The Active Pharmaceutical Ingredients (API) market is a dynamic and complex industry, characterized by continuous innovation and evolution. According to industry estimates, the global API market was valued at USD 150 billion in 2020. This growth is driven by the increasing demand for new drugs and the need for more efficient manufacturing processes. Sterile manufacturing and API characterization methods, such as polymorphism studies, particle size analysis, and drug absorption studies, play a crucial role in ensuring the quality and safety of APIs. In vitro studies, including bioavailability and solubility enhancement, are essential for predicting drug behavior in the human body.
- Regulatory submissions, process control, and continuous manufacturing are also key areas of focus, as companies strive to meet stringent regulatory requirements and improve process efficiency. Pharmaceutical packaging, clinical trial materials, and drug product development are integral parts of the API market, with a growing emphasis on data analytics and process analytical technology to optimize production and improve product quality. Toxicology studies, drug metabolism, dosage form design, and regulatory submissions are also critical components of the API development process. Microfluidics technology and data analytics are emerging trends in the API market, offering potential for increased efficiency, cost savings, and improved product quality.
- The market is expected to remain competitive, with companies investing in research and development to stay ahead of the curve. Drug elimination, in vivo studies, and quality by design are other areas of ongoing research and development in the API industry.
We can help! Our analysts can customize this active pharmaceutical ingredients market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Manufacturing Type
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Market characteristics analysis
4 Market Sizing
- 4.1 Market definition
- Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5.1 Global Active Pharmaceutical Ingredients Market 2019 - 2023
- Historic Market Size - Data Table on Global Active Pharmaceutical Ingredients Market 2019 - 2023 ($ billion)
- 5.2 Manufacturing Type segment analysis 2019 - 2023
- Historic Market Size - Manufacturing Type Segment 2019 - 2023 ($ billion)
- 5.3 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)
- 5.4 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.5 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Active Pharmaceutical Ingredients Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Manufacturing Type
- 8.1 Market segments
- Chart on Manufacturing Type - Market share (2024-2029) (%)
- Data Table on Manufacturing Type - Market share (2024-2029) (%)
- 8.2 Comparison by Manufacturing Type
- Chart on Comparison by Manufacturing Type
- Data Table on Comparison by Manufacturing Type
- 8.3 Captive APIs - Market size and forecast (2024-2029)
- Chart on Captive APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Captive APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Captive APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Captive APIs - Year-over-year growth (2024-2029) (%)
- 8.4 Contract APIs - Market size and forecast (2024-2029)
- Chart on Contract APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Contract APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Contract APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Contract APIs - Year-over-year growth (2024-2029) (%)
- 8.5 Market opportunity by Manufacturing Type
- Market opportunity by Manufacturing Type ($ billion)
- Data Table on Market opportunity by Manufacturing Type ($ billion)
9 Market Segmentation by Type
- 9.1 Market segments
- Chart on Type - Market share (2024-2029) (%)
- Data Table on Type - Market share (2024-2029) (%)
- 9.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 9.3 Innovative APIs - Market size and forecast (2024-2029)
- Chart on Innovative APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Innovative APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Innovative APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Innovative APIs - Year-over-year growth (2024-2029) (%)
- 9.4 Generic APIs - Market size and forecast (2024-2029)
- Chart on Generic APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Generic APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Generic APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Generic APIs - Year-over-year growth (2024-2029) (%)
- 9.5 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)
10 Market Segmentation by Synthesis Method
- 10.1 Market segments
- Chart on Synthesis Method - Market share (2024-2029) (%)
- Data Table on Synthesis Method - Market share (2024-2029) (%)
- 10.2 Comparison by Synthesis Method
- Chart on Comparison by Synthesis Method
- Data Table on Comparison by Synthesis Method
- 10.3 Biotech APIs - Market size and forecast (2024-2029)
- Chart on Biotech APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Biotech APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Biotech APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Biotech APIs - Year-over-year growth (2024-2029) (%)
- 10.4 Synthetic APIs - Market size and forecast (2024-2029)
- Chart on Synthetic APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Synthetic APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Synthetic APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Synthetic APIs - Year-over-year growth (2024-2029) (%)
- 10.5 Market opportunity by Synthesis Method
- Market opportunity by Synthesis Method ($ billion)
- Data Table on Market opportunity by Synthesis Method ($ billion)
11 Market Segmentation by Application
- 11.1 Market segments
- Chart on Application - Market share (2024-2029) (%)
- Data Table on Application - Market share (2024-2029) (%)
- Chart on Nephrology - Market size and forecast (2024-2029) ($ billion)
- Data Table on Nephrology - Market size and forecast (2024-2029) ($ billion)
- Chart on Nephrology - Year-over-year growth (2024-2029) (%)
- Data Table on Nephrology - Year-over-year growth (2024-2029) (%)
- 11.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- Chart on Ophthalmology - Market size and forecast (2024-2029) ($ billion)
- Data Table on Ophthalmology - Market size and forecast (2024-2029) ($ billion)
- Chart on Ophthalmology - Year-over-year growth (2024-2029) (%)
- Data Table on Ophthalmology - Year-over-year growth (2024-2029) (%)
- 11.3 Cardiovascular Diseases - Market size and forecast (2024-2029)
- Chart on Cardiovascular Diseases - Market size and forecast (2024-2029) ($ billion)
- Data Table on Cardiovascular Diseases - Market size and forecast (2024-2029) ($ billion)
- Chart on Cardiovascular Diseases - Year-over-year growth (2024-2029) (%)
- Data Table on Cardiovascular Diseases - Year-over-year growth (2024-2029) (%)
- Chart on Anti-Infectives - Market size and forecast (2024-2029) ($ billion)
- Data Table on Anti-Infectives - Market size and forecast (2024-2029) ($ billion)
- Chart on Anti-Infectives - Year-over-year growth (2024-2029) (%)
- Data Table on Anti-Infectives - Year-over-year growth (2024-2029) (%)
- 11.4 Oncology - Market size and forecast (2024-2029)
- Chart on Oncology - Market size and forecast (2024-2029) ($ billion)
- Data Table on Oncology - Market size and forecast (2024-2029) ($ billion)
- Chart on Oncology - Year-over-year growth (2024-2029) (%)
- Data Table on Oncology - Year-over-year growth (2024-2029) (%)
- Chart on Diabetes - Market size and forecast (2024-2029) ($ billion)
- Data Table on Diabetes - Market size and forecast (2024-2029) ($ billion)
- Chart on Diabetes - Year-over-year growth (2024-2029) (%)
- Data Table on Diabetes - Year-over-year growth (2024-2029) (%)
- 11.5 CNS and Neurology - Market size and forecast (2024-2029)
- Chart on CNS and Neurology - Market size and forecast (2024-2029) ($ billion)
- Data Table on CNS and Neurology - Market size and forecast (2024-2029) ($ billion)
- Chart on CNS and Neurology - Year-over-year growth (2024-2029) (%)
- Data Table on CNS and Neurology - Year-over-year growth (2024-2029) (%)
- Chart on Respiratory Diseases - Market size and forecast (2024-2029) ($ billion)
- Data Table on Respiratory Diseases - Market size and forecast (2024-2029) ($ billion)
- Chart on Respiratory Diseases - Year-over-year growth (2024-2029) (%)
- Data Table on Respiratory Diseases - Year-over-year growth (2024-2029) (%)
- 11.6 Orthopedic - Market size and forecast (2024-2029)
- Chart on Orthopedic - Market size and forecast (2024-2029) ($ billion)
- Data Table on Orthopedic - Market size and forecast (2024-2029) ($ billion)
- Chart on Orthopedic - Year-over-year growth (2024-2029) (%)
- Data Table on Orthopedic - Year-over-year growth (2024-2029) (%)
- Chart on Other - Market size and forecast (2024-2029) ($ billion)
- Data Table on Other - Market size and forecast (2024-2029) ($ billion)
- Chart on Other - Year-over-year growth (2024-2029) (%)
- Data Table on Other - Year-over-year growth (2024-2029) (%)
- 11.7 Endocrinology - Market size and forecast (2024-2029)
- Chart on Endocrinology - Market size and forecast (2024-2029) ($ billion)
- Data Table on Endocrinology - Market size and forecast (2024-2029) ($ billion)
- Chart on Endocrinology - Year-over-year growth (2024-2029) (%)
- Data Table on Endocrinology - Year-over-year growth (2024-2029) (%)
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
- 11.8 Pulmonology - Market size and forecast (2024-2029)
- Chart on Pulmonology - Market size and forecast (2024-2029) ($ billion)
- Data Table on Pulmonology - Market size and forecast (2024-2029) ($ billion)
- Chart on Pulmonology - Year-over-year growth (2024-2029) (%)
- Data Table on Pulmonology - Year-over-year growth (2024-2029) (%)
- 11.9 Gastroenterology - Market size and forecast (2024-2029)
- Chart on Gastroenterology - Market size and forecast (2024-2029) ($ billion)
- Data Table on Gastroenterology - Market size and forecast (2024-2029) ($ billion)
- Chart on Gastroenterology - Year-over-year growth (2024-2029) (%)
- Data Table on Gastroenterology - Year-over-year growth (2024-2029) (%)
12 Market Segmentation by End-User
- 12.1 Market segments
- Chart on End-User - Market share (2024-2029) (%)
- Data Table on End-User - Market share (2024-2029) (%)
- 12.2 Comparison by End-User
- Chart on Comparison by End-User
- Data Table on Comparison by End-User
- 12.3 Pharmaceutical Companies - Market size and forecast (2024-2029)
- Chart on Pharmaceutical Companies - Market size and forecast (2024-2029) ($ billion)
- Data Table on Pharmaceutical Companies - Market size and forecast (2024-2029) ($ billion)
- Chart on Pharmaceutical Companies - Year-over-year growth (2024-2029) (%)
- Data Table on Pharmaceutical Companies - Year-over-year growth (2024-2029) (%)
- 12.4 Biotechnology Companies - Market size and forecast (2024-2029)
- Chart on Biotechnology Companies - Market size and forecast (2024-2029) ($ billion)
- Data Table on Biotechnology Companies - Market size and forecast (2024-2029) ($ billion)
- Chart on Biotechnology Companies - Year-over-year growth (2024-2029) (%)
- Data Table on Biotechnology Companies - Year-over-year growth (2024-2029) (%)
- 12.5 Contract Research Organizations (CROs) - Market size and forecast (2024-2029)
- Chart on Contract Research Organizations (CROs) - Market size and forecast (2024-2029) ($ billion)
- Data Table on Contract Research Organizations (CROs) - Market size and forecast (2024-2029) ($ billion)
- Chart on Contract Research Organizations (CROs) - Year-over-year growth (2024-2029) (%)
- Data Table on Contract Research Organizations (CROs) - Year-over-year growth (2024-2029) (%)
- 12.6 Academic/Research Institutes - Market size and forecast (2024-2029)
- Chart on Academic/Research Institutes - Market size and forecast (2024-2029) ($ billion)
- Data Table on Academic/Research Institutes - Market size and forecast (2024-2029) ($ billion)
- Chart on Academic/Research Institutes - Year-over-year growth (2024-2029) (%)
- Data Table on Academic/Research Institutes - Year-over-year growth (2024-2029) (%)
- 12.7 Market opportunity by End-User
- Market opportunity by End-User ($ billion)
- Data Table on Market opportunity by End-User ($ billion)
13 Market Segmentation by Potency
- 13.1 Market segments
- Chart on Potency - Market share (2024-2029) (%)
- Data Table on Potency - Market share (2024-2029) (%)
- 13.2 Comparison by Potency
- Chart on Comparison by Potency
- Data Table on Comparison by Potency
- 13.3 High Potency APIs (HPAPIs) - Market size and forecast (2024-2029)
- Chart on High Potency APIs (HPAPIs) - Market size and forecast (2024-2029) ($ billion)
- Data Table on High Potency APIs (HPAPIs) - Market size and forecast (2024-2029) ($ billion)
- Chart on High Potency APIs (HPAPIs) - Year-over-year growth (2024-2029) (%)
- Data Table on High Potency APIs (HPAPIs) - Year-over-year growth (2024-2029) (%)
- 13.4 Low Potency APIs - Market size and forecast (2024-2029)
- Chart on Low Potency APIs - Market size and forecast (2024-2029) ($ billion)
- Data Table on Low Potency APIs - Market size and forecast (2024-2029) ($ billion)
- Chart on Low Potency APIs - Year-over-year growth (2024-2029) (%)
- Data Table on Low Potency APIs - Year-over-year growth (2024-2029) (%)
- 13.5 Market opportunity by Potency
- Market opportunity by Potency ($ billion)
- Data Table on Market opportunity by Potency ($ billion)
14 Customer Landscape
- 14.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
15 Geographic Landscape
- 15.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 15.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 15.3 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- 15.4 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- 15.5 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- 15.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- 15.7 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 15.8 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 15.9 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 15.10 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 15.11 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 15.12 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 15.13 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 15.14 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 15.15 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 15.16 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 15.17 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
- 15.18 APAC - Market size and forecast (2024-2029)
- Chart on APAC - Market size and forecast (2024-2029) ($ billion)
- Data Table on APAC - Market size and forecast (2024-2029) ($ billion)
- Chart on APAC - Year-over-year growth (2024-2029) (%)
- Data Table on APAC - Year-over-year growth (2024-2029) (%)
- 15.19 South America - Market size and forecast (2024-2029)
- Chart on South America - Market size and forecast (2024-2029) ($ billion)
- Data Table on South America - Market size and forecast (2024-2029) ($ billion)
- Chart on South America - Year-over-year growth (2024-2029) (%)
- Data Table on South America - Year-over-year growth (2024-2029) (%)
- 15.20 Middle East & Africa - Market size and forecast (2024-2029)
- Chart on Middle East & Africa - Market size and forecast (2024-2029) ($ billion)
- Data Table on Middle East & Africa - Market size and forecast (2024-2029) ($ billion)
- Chart on Middle East & Africa - Year-over-year growth (2024-2029) (%)
- Data Table on Middle East & Africa - Year-over-year growth (2024-2029) (%)
- 15.21 Egypt - Market size and forecast (2024-2029)
- Chart on Egypt - Market size and forecast (2024-2029) ($ billion)
- Data Table on Egypt - Market size and forecast (2024-2029) ($ billion)
- Chart on Egypt - Year-over-year growth (2024-2029) (%)
- Data Table on Egypt - Year-over-year growth (2024-2029) (%)
- 15.22 UAE - Market size and forecast (2024-2029)
- Chart on UAE - Market size and forecast (2024-2029) ($ billion)
- Data Table on UAE - Market size and forecast (2024-2029) ($ billion)
- Chart on UAE - Year-over-year growth (2024-2029) (%)
- Data Table on UAE - Year-over-year growth (2024-2029) (%)
- 15.23 Oman - Market size and forecast (2024-2029)
- Chart on Oman - Market size and forecast (2024-2029) ($ billion)
- Data Table on Oman - Market size and forecast (2024-2029) ($ billion)
- Chart on Oman - Year-over-year growth (2024-2029) (%)
- Data Table on Oman - Year-over-year growth (2024-2029) (%)
- 15.24 Argentina - Market size and forecast (2024-2029)
- Chart on Argentina - Market size and forecast (2024-2029) ($ billion)
- Data Table on Argentina - Market size and forecast (2024-2029) ($ billion)
- Chart on Argentina - Year-over-year growth (2024-2029) (%)
- Data Table on Argentina - Year-over-year growth (2024-2029) (%)
- 15.25 KSA - Market size and forecast (2024-2029)
- Chart on KSA - Market size and forecast (2024-2029) ($ billion)
- Data Table on KSA - Market size and forecast (2024-2029) ($ billion)
- Chart on KSA - Year-over-year growth (2024-2029) (%)
- Data Table on KSA - Year-over-year growth (2024-2029) (%)
16 Drivers, Challenges, and Opportunity/Restraints
- 16.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 16.4 Market opportunities/restraints
17 Competitive Landscape
- 17.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 17.3 Landscape disruption
- Overview on factors of disruption
- 17.4 Industry risks
- Impact of key risks on business
18 Competitive Analysis
- 18.2 Company ranking index
- 18.3 Market positioning of companies
- Matrix on companies position and classification
- 18.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
- 18.5 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key news
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 18.6 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product / Service
- Aurobindo Pharma Ltd. - Key offerings
- SWOT
- 18.7 Cadila Pharmaceuticals Ltd.
- Cadila Pharmaceuticals Ltd. - Overview
- Cadila Pharmaceuticals Ltd. - Product / Service
- Cadila Pharmaceuticals Ltd. - Key offerings
- SWOT
- 18.8 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 18.9 Dr Reddys Laboratories Ltd.
- Dr Reddys Laboratories Ltd. - Overview
- Dr Reddys Laboratories Ltd. - Business segments
- Dr Reddys Laboratories Ltd. - Key news
- Dr Reddys Laboratories Ltd. - Key offerings
- Dr Reddys Laboratories Ltd. - Segment focus
- SWOT
- 18.10 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 18.11 Koninklijke DSM NV
- Koninklijke DSM NV - Overview
- Koninklijke DSM NV - Business segments
- Koninklijke DSM NV - Key news
- Koninklijke DSM NV - Key offerings
- Koninklijke DSM NV - Segment focus
- SWOT
- 18.12 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 18.13 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 18.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 18.15 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 18.16 Sun Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd. - Overview
- Sun Pharmaceutical Industries Ltd. - Product / Service
- Sun Pharmaceutical Industries Ltd. - Key news
- Sun Pharmaceutical Industries Ltd. - Key offerings
- SWOT
- 18.17 Teva Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key news
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Segment focus
- SWOT
- 18.18 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
19 Appendix
- 19.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 19.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 19.4 Research methodology
- 19.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 19.9 360 degree market analysis
- 360 degree market analysis
- 19.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
